申请人:The Trustees of Columbia University in the City of New York
公开号:US20180094322A1
公开(公告)日:2018-04-05
The present invention provides a biomarker, namely CDX2, and surrogate CDX2 biomarkers, the expression level of which is useful in predicting response of cancer patients to therapy with an EGFR inhibitor.